

For Lab Use Only	Facility Name	Ordering Physician Name Last First
	Address	Physician NPI No.
	City, State, Zip	Physician Phone No. () ()
	Facility Phone Number () ()	Report Fax Number () ()
Patient Name (Last) (First)		Insurance Info: Attach a copy of front & back of Insurance card or face sheet <input type="checkbox"/> Private Ins/PPO <input type="checkbox"/> Medicare <input type="checkbox"/> Medi-Cal <input type="checkbox"/> Patient <input type="checkbox"/> Client
Unique ID or MRN	DOB-Required	Sex M F
Patient's Phone Number () ()	Collection Date & Time	Collection by- Required
Copy to: First Name Last Name		Address
		City, State, Zip
Copy to complete address for mailing:		ICD Code(s) * - REQUIRED INFORMATION
		Physician Signature: _____ Date: _____ Time: _____

Each individual test and CMS approved panel must have ICD code(s) to indicate the medical necessity of the test requested. Please provide all applicable ICD code(s) for the tests ordered. @ Tests for Medicare Patients Must be screened to determine if an Advanced Beneficiary Notice (ABN) is required. An ABN must be provided to the Medicare patient if there is a reason to believe Medicare will deny the test. Medicare may deny tests due to frequency. Medicare does not generally cover routine screening tests. Continued on page 3.

SAMPLE TYPE

- | | | |
|--|---|---|
| <input type="checkbox"/> Peripheral Blood | <input type="checkbox"/> Fresh Tissue; site _____ Type _____ | <input type="checkbox"/> Fluid; type _____ |
| <input type="checkbox"/> Bone Marrow Aspirate | <input type="checkbox"/> Paraffin Block; site _____ Block No. _____ | <input type="checkbox"/> Slides; site _____ |
| ■ % neoplastic cells in sample submitted _____ | ● % tumor in sample submitted _____ | <input type="checkbox"/> Slide No. _____ |

CLINICAL HISTORY

Signs/Symptoms: _____ Prior Diagnosis: _____
Suspected Diagnosis: _____

MOLECULAR PATHOLOGY

- | | |
|---|---|
| <p>√ Test Name</p> <ul style="list-style-type: none"> <input type="checkbox"/> Alpha Thalassemia/Hb Constant Spring <input type="checkbox"/> AML Prognosis Assay- NMP1 & FLT3■ <input type="checkbox"/> B-Cell Clonality <i>Include Pathology report</i> <input type="checkbox"/> BCR-ABL ◆ <input type="checkbox"/> BCR-ABL Kinase Domain Mutation Analysis ◆ <input type="checkbox"/> Beta Thalassemia Sequencing <input type="checkbox"/> BRAF by PCR <i>Include Pathology report</i>● <input type="checkbox"/> Calreticulin Mutation Detection <input type="checkbox"/> CEBPA by sequencing ■ <input type="checkbox"/> IDH1/IDH2 Mutation Panel <i>Include Pathology report</i>● <input type="checkbox"/> KIT Mutation Analysis(exons 8 & 17) ◆■ <input type="checkbox"/> KIT D816V <i>Include Pathology report</i> <input type="checkbox"/> Factor V Leiden <input type="checkbox"/> Familial Gastric Cancer (CDH1) by sequencing, Blood or FFPE Normal Tissue <input type="checkbox"/> Familial Gastric Cancer (CDH1), Blood or FFPE Normal Tissue
Known Mutation, Exon: _____ <input type="checkbox"/> Familial Gastric Cancer (CDH1 deletion/duplication analysis) by MLPA, Blood
<i>(complete CDH1 requisition)</i>
<i>CDH1 requisition</i> can be found at http://www.stanfordlab.com/pages/test-requisitions.htm | <p>√ Test Name</p> <ul style="list-style-type: none"> <input type="checkbox"/> JAK2 V617F (1849G>T), Quantitative <input type="checkbox"/> KRAS/NRAS Mutation Detection <i>Include Pathology report</i>● <input type="checkbox"/> Stanford Solid Tumor Actionable Mutation Panel
by Next Gen Seq. <i>Include Pathology report</i> ●▼ <input type="checkbox"/> MGMT by Methylation Specific PCR● <input type="checkbox"/> MYD88 Mutation L265P, 794T>C ■ Check box <input type="checkbox"/> if unable to estimate % neoplastic cells <input type="checkbox"/> Myeloid Next Generation Sequencing Assay ■▼ <input type="checkbox"/> PML-RARα t(15;17),Quant◆ <input type="checkbox"/> Prothrombin-20210A Mutation <input type="checkbox"/> SF3B1 Mutation ■ Check box <input type="checkbox"/> if unable to estimate % neoplastic cells <input type="checkbox"/> T-Cell Clonality by PCR <i>Include Pathology report</i> <input type="checkbox"/> VH Mutation Analysis <input type="checkbox"/> Microsatellite Instability by PCR Check if whole blood submitted <input type="checkbox"/>
NOTE: submit a normal block or peripheral blood with tumor sample
Include Pathology report● <input type="checkbox"/> Extract DNA for future testing <input type="checkbox"/> Extract RNA for future testing <input type="checkbox"/> Other _____ <p>◆ RNA Studies –ship on wet ice ■ Provide the % neoplastic cells in sample submitted
● Provide the % tumor in sample submitted
▼ A full list of targeted regions for the Sequencing Assays can be found at www.stanfordlab.com</p> |
|---|---|

For Lab Use Only		Facility Name		Ordering Physician Name Last First	
		Address		Physician NPI No.	
		City, State, Zip		Physician Phone No. ()	
		Facility Phone Number ()		Report Fax Number ()	
Patient Name (Last) (First)			Insurance Info: Attach a copy of front & back of Insurance card or face sheet <input type="checkbox"/> Private Ins/PPO <input type="checkbox"/> Medicare <input type="checkbox"/> Medi-Cal <input type="checkbox"/> Patient <input type="checkbox"/> Client		
Unique ID or MRN		DOB-Required	Sex M F	Responsible Party (Please Print)	
Patient's Phone Number ()	Collection Date & Time	Collection by- Required		Address	
Copy to: First Name	Last Name		City, State, Zip		
Copy to complete address for mailing:			ICD Code(s) * - REQUIRED INFORMATION		
			Physician Signature:	Date:	Time:
<small>Each individual test and CMS approved panel must have ICD code(s) to indicate the medical necessity of the test requested. Please provide all applicable ICD code(s) for the tests ordered. @ Tests for Medicare Patients Must be screened to determine if an Advanced Beneficiary Notice (ABN) is required. An ABN must be provided to the Medicare patient if there is a reason to believe Medicare will deny the test. Medicare may deny tests due to frequency. Medicare does not generally cover routine screening tests. Continued on page 3.</small>					
SAMPLE TYPE					
<input type="checkbox"/> Peripheral Blood		<input type="checkbox"/> Fresh Tissue; site _____ Type _____			
<input type="checkbox"/> Fluid; type _____		<input type="checkbox"/> Paraffin Block; site _____ Block No. _____			
CLINICAL HISTORY					
Signs/Symptoms: _____			Prior Diagnosis _____		
Suspected Diagnosis: _____					
MOLECULAR PATHOLOGY					
√ Test Name			√ Test Name		
<input type="checkbox"/> Achondroplasia / Hypochondroplasia			<input type="checkbox"/> FGFR1 Craniosynostosis		
<input type="checkbox"/> Alpha Thalassemia/Hb Constant Spring			<input type="checkbox"/> FGFR2 Craniosynostosis		
<input type="checkbox"/> Beta Thalassemia Sequencing			<input type="checkbox"/> FGFR3 Muenke		
<input type="checkbox"/> Biotinidase Sequencing Assay			<input type="checkbox"/> Fragile X		
<input type="checkbox"/> CF 39, Cystic Fibrosis, DNA			<input type="checkbox"/> Hemochromatosis Genotyping Analysis		
<input type="checkbox"/> CF Poly-T Analysis			<input type="checkbox"/> Huntington Disease Analysis		
<input type="checkbox"/> CFTR Screen by Sequencing (Unidirectional)			<input type="checkbox"/> Pendred Syndrome by sequencing		
<input type="checkbox"/> CFTR Deletion/Duplication Analysis by MLPA			<input type="checkbox"/> Prader-Willi Syndrome (PWS), RNA ◆		
<input type="checkbox"/> CFTR Diagnostic Sequencing (Bidirectional DNA Full gene)			<input type="checkbox"/> Prothrombin-20210A Mutation		
<input type="checkbox"/> CFTR Sequencing Assay, Exon specific			<input type="checkbox"/> Maternal Cell Contamination-Fetal Sample and Maternal Cell Contamination- <i>Whole Blood Maternal Sample (4mL EDTA) required with prenatal sample.</i>		
List mutation(s): _____			<input type="checkbox"/> Extract DNA for future testing		
<input type="checkbox"/> Connexin 26, Sequencing			<input type="checkbox"/> Extract RNA for future testing		
<input type="checkbox"/> Connexin 30			<input type="checkbox"/> Other: _____		
<input type="checkbox"/> Duchenne and Becker Muscular Dystrophy by MLPA			<input type="checkbox"/> Familial Gastric Cancer, Whole Blood ○ (CDH1 deletion/duplication analysis) by MLPA		
<input type="checkbox"/> Factor V Leiden			◆ RNA studies ship on wet ice		
<input type="checkbox"/> Familial Gastric Cancer (CDH1) by sequencing ○ Whole Blood or FFPE Normal Tissue			○ Complete CDH1 requisition <i>CDH1 requisition</i> can be found at http://www.stanfordlab.com/pages/test_requisitions.htm		
<input type="checkbox"/> Familial Gastric Cancer (CDH1) Known Mutation, ○ Whole Blood or FFPE Normal Tissue					
Exon: _____					

STANFORD SPECIMEN REQUIREMENTS

For Specimen collection questions you may call the testing laboratory at the phone number listed next to the department name or contact our Customer Service department at 1-877-717-3733. Specimen requirements can also be found on www.stanfordlab.com.

MOLECULAR PATHOLOGY		Lab Phone Number (650) 723-6574
Whole Blood	<ul style="list-style-type: none"> • Minimum 4 mL • Lavender-top (EDTA) tubes <p>RNA Studies –ship on wet ice, DNA Studies ship at room temperature ■ Provide % neoplastic cells in sample submitted</p>	
Bone Marrow	<ul style="list-style-type: none"> • 1-2 mL Bone Marrow • Lavender-top (EDTA) tubes • Maintain specimen at room temperature <p>■ Provide % neoplastic cells in sample submitted</p>	
Tissue <i>Enclose a copy of the patient's Pathology Report</i>	<ul style="list-style-type: none"> • Non-decalcified formalin-fixed, paraffin-embedded (FFPE) at room temperature • Provide % tumor in sample submitted or H & E stained slide of block submitted 	
Fluid	<ul style="list-style-type: none"> • Volume varies, contact laboratory • Sterile tube • Maintain specimen at room temperature 	

Ship to:
If shipping Friday check for Saturday delivery

Phone: 1 (877) 717-3733
 Fax delivery notification to: (650) 724-4758

Stanford Anatomic Pathology and Clinical Laboratories
Attn: Specimen Processing
3375 Hillview Ave
Palo Alto, CA 94304

Shipper's Responsibility: The shipper is required to comply with the rules and guidelines for transport of medical specimens as set forth by the United States government, the government of the country of origin and international regulatory agencies. Failure to follow instructions for packaging and shipping specimens can result in the delay, loss or destruction of your specimens. Stanford University Medical Center Clinical Laboratories will not be held responsible for any liability attributable to the shipper's improper actions or failure to comply with regulations.

Continued from page 1 or 2

Section 1862(a)(1)(A) of the Social Security Act states, “no payment may be made under Part A or Part B for any expense incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of any illness or to improve the functioning of a malformed body member.” Tests submitted for Medicare reimbursement must meet program requirements or the claim may be denied.

@ This test is subject to Medicare NCD or LCD, coverage is limited to certain diagnoses that support medical necessity.

* ICD Code(s) based on present CMS guidelines.

Patient's First Name: _____

Patient's Last Name: _____

Patient's MRN: _____

Or Affix Label Here



Stanford
HEALTH CARE
STANFORD MEDICINE

Advance Beneficiary Notice of Noncoverage (ABN)

NOTE: If Medicare doesn't pay for **D.** below, you may have to pay.

Medicare does not pay for everything, even some care that you or your health care provider have good reason to think you need. We expect Medicare may not pay for the **D.** below.

D.	E. Reason Medicare May Not Pay:	F. Estimated Cost

WHAT YOU NEED TO DO NOW:

- Read this notice, so you can make an informed decision about your care.
- Ask us any questions that you may have after you finish reading.
- Choose an option below about whether to receive the **D.** listed above.

Note: If you choose Option 1 or 2, we may help you to use any other insurance that you might have, but Medicare cannot require us to do this.

G. OPTIONS: Check only one box. We cannot choose a box for you.

- OPTION 1.** I want the **D.** listed above. You may ask to be paid now, but I also want Medicare billed for an official decision on payment, which is sent to me on a Medicare Summary Notice (MSN). I understand that if Medicare doesn't pay, I am responsible for payment, but I **can appeal to Medicare** by following the directions on the MSN. If Medicare does pay, you will refund any payments I made to you, less co-pays or deductibles.
- OPTION 2.** I want the **D.** listed above, but do not bill Medicare. You may ask to be paid now as I am responsible for payment. **I cannot appeal if Medicare is not billed.**
- OPTION 3.** I don't want the **D.** listed above. I understand with this choice I am **not responsible for payment, and I cannot appeal to see if Medicare would pay.**

H. Additional Information:

This notice gives our opinion, not an official Medicare decision. If you have other questions on this notice or Medicare billing, call **1-800-MEDICARE** (1-800-633-4227/TTY: 1-877-486-2048).

Signing below means that you have received and understand this notice. You also receive a copy.

I. Signature:	J. Date:

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0938-0566. The time required to complete this information collection is estimated to average 7 minutes per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Baltimore, Maryland 21244-1850.